Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up - PubMed (original) (raw)
. 2010 Jan 1;28(1):136-41.
doi: 10.1200/JCO.2009.24.0945. Epub 2009 Nov 23.
Affiliations
- PMID: 19933914
- DOI: 10.1200/JCO.2009.24.0945
Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up
Ronald C Chen et al. J Clin Oncol. 2010.
Abstract
PURPOSE The optimal treatment for early-stage, lymphocyte-predominant Hodgkin's lymphoma (LPHL) is not well defined. Treatment has become less aggressive over time in an attempt to reduce iatrogenic complications, such as cardiac mortality and second cancers, but long-term efficacy is unclear. We present the long-term outcome of patients treated at a single institution. PATIENTS AND METHODS The study population includes 113 patients with stage I or II LPHL treated between 1970 and 2005. Pathologic diagnosis for all patients was confirmed using standard criteria. Ninety-three patients received radiation therapy (RT) alone, 13 received RT with chemotherapy, and seven received chemotherapy alone. Among patients treated with RT, 25 received limited-field, 35 received regional-field, and 46 received extended-field RT. Results Median follow-up was 136 months. Ten-year progression-free survival (PFS) rates were 85% (stage I) and 61% (stage II); overall survival (OS) rates were 94% and 97% for stages I and II, respectively. PFS and OS did not differ among patients who received limited-field, regional-field, or extended-field RT. In contrast, six of seven patients who received chemotherapy alone without RT developed early disease progression and required salvage treatment. Multivariable analysis adjusting for extent of RT, clinical stage, sex, and use of chemotherapy confirmed that the extent of RT was not significantly associated with PFS (P = .67) or OS (P = .99). The addition of chemotherapy to RT did not improve PFS or OS compared with RT alone. CONCLUSION RT alone leads to sustained disease control and high long-term survival rates in patients with early-stage LPHL. This study supports the use of limited-field RT alone to treat this disease.
Similar articles
- Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group.
Wirth A, Yuen K, Barton M, Roos D, Gogna K, Pratt G, Macleod C, Bydder S, Morgan G, Christie D. Wirth A, et al. Cancer. 2005 Sep 15;104(6):1221-9. doi: 10.1002/cncr.21303. Cancer. 2005. PMID: 16094666 - Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.
Campbell BA, Voss N, Pickles T, Morris J, Gascoyne RD, Savage KJ, Connors JM. Campbell BA, et al. J Clin Oncol. 2008 Nov 10;26(32):5170-4. doi: 10.1200/JCO.2007.15.1001. Epub 2008 Oct 6. J Clin Oncol. 2008. PMID: 18838714 - Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma.
Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D, Shankar A, Dörffel W, Wallace WH, Schellong G, Robert A, Körholz D, Oberlin O, Hall GW, Landman-Parker J. Mauz-Körholz C, et al. Cancer. 2007 Jul 1;110(1):179-85. doi: 10.1002/cncr.22762. Cancer. 2007. PMID: 17526010 - The impact of radiotherapy fields in the treatment of patients with choroid plexus carcinoma.
Mazloom A, Wolff JE, Paulino AC. Mazloom A, et al. Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):79-84. doi: 10.1016/j.ijrobp.2009.07.1701. Epub 2009 Dec 11. Int J Radiat Oncol Biol Phys. 2010. PMID: 20004534 Review. - Nodular lymphocyte-predominant Hodgkin's lymphoma.
Nogovà L, Diehl V, Engert A; German Hodgkin Study Group. Nogovà L, et al. Curr Hematol Malig Rep. 2006 Mar;1(1):60-5. doi: 10.1007/s11899-006-0019-2. Curr Hematol Malig Rep. 2006. PMID: 20425333 Review.
Cited by
- Autoimmune hemolytic anemia and nodular lymphocyte-predominant hodgkin lymphoma: a rare association.
Salmeron G, Molina TJ, Fieschi C, Zagdanski AM, Brice P, Sibon D. Salmeron G, et al. Case Rep Hematol. 2013;2013:567289. doi: 10.1155/2013/567289. Epub 2013 Apr 28. Case Rep Hematol. 2013. PMID: 23710384 Free PMC article. - Open questions in the management of nodular lymphocyte predominant hodgkin lymphoma.
Tyran M, Gonzague L, Bouabdallah R, Resbeut M. Tyran M, et al. Case Rep Hematol. 2014;2014:427613. doi: 10.1155/2014/427613. Epub 2014 Feb 20. Case Rep Hematol. 2014. PMID: 24772357 Free PMC article. - Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.
Eichenauer DA, Engert A. Eichenauer DA, et al. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):324-328. doi: 10.1182/asheducation-2017.1.324. Hematology Am Soc Hematol Educ Program. 2017. PMID: 29222274 Free PMC article. Review. - Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up.
Pugliese N, Picardi M, Della Pepa R, Giordano C, Muriano F, Leone A, Delle Cave G, D'Ambrosio A, Marafioti V, Rascato MG, Russo D, Mascolo M, Pane F. Pugliese N, et al. Cancers (Basel). 2021 Apr 7;13(8):1760. doi: 10.3390/cancers13081760. Cancers (Basel). 2021. PMID: 33917062 Free PMC article. - Nodular lymphocyte-predominant Hodgkin lymphoma: advances in disease biology, risk stratification, and treatment.
Salvaris RT, Allanson BM, Collins G, Cheah C. Salvaris RT, et al. Haematologica. 2024 Nov 1;109(11):3476-3487. doi: 10.3324/haematol.2024.285903. Haematologica. 2024. PMID: 39234861 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical